-
Mashup Score: 0
An FDA advisory committee recommended that a proposed indication for olaparib with abiraterone acetate as first-line treatment for metastatic castration-resistant prostate cancer be limited to patients whose tumors have BRCA mutations.The Oncologic Drugs Advisory Committee voted 11 to 1 in favor of the restriction. One committee member abstained.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Positive topline results were announced from a study comparing TAVT-45, a formulation of abiraterone acetate that is easier to swallow, to the current formulation.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
TAVT-45 showed therapeutic equivalence to #Zytiga, the currently approved formulation, in patients with metastatic castration-resistant and -sensitive #prostatecancer. #pcsm https://t.co/YMF2DGFhrp
-
-
Mashup Score: 0
Positive topline results were announced from a study comparing TAVT-45, a formulation of abiraterone acetate that is easier to swallow, to the current formulation.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A new formulation of abiraterone acetate, TAVT-45, demonstrated therapeutic equivalence to #Zytiga, the currently approved formulation, in patients with metastatic castration-resistant prostate cancer & metastatic castration-sensitive #prostatecancer. https://t.co/YMF2DGFhrp
-
-
Mashup Score: 0For mCSPC, Abiraterone Plus ADT and Docetaxel Improves rPFS - 3 year(s) ago
In men with de novo metastatic castration-sensitive prostate cancer, the addition of abiraterone (Zytiga, Janssen) and prednisone to androgen deprivation therapy and docetaxel significantly improved radiographic progression-free survival , according to results from the phase 3 PEACE-1 study.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Abiraterone plus ADT and docetaxel significantly improved radiographic progression-free survival in men with de novo mCSPC. https://t.co/ElbhE7flpE @ASCO @GustaveRoussy #zytiga #docetaxel #abirateron #prostatecancer #ASCO2021
-
-
Mashup Score: 1For mCSPC, Abiraterone Plus ADT and Docetaxel Improves rPFS - 3 year(s) ago
In men with de novo metastatic castration-sensitive prostate cancer, the addition of abiraterone (Zytiga, Janssen) and prednisone to androgen deprivation therapy and docetaxel significantly improved radiographic progression-free survival , according to results from the phase 3 PEACE-1 study.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Abiraterone plus ADT and docetaxel significantly improved radiographic progression-free survival in men with de novo mCSPC. https://t.co/ElbhE7flpE @ASCO @GustaveRoussy #zytiga #docetaxel #abirateron #prostatecancer #ASCO2021
-
-
Mashup Score: 0Unexpected Race-Based Findings in Novel Prostate Cancer Study - 3 year(s) ago
Differing toxicity severity seen among Black and white patients on identical regimen
Source: www.medpagetoday.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a study, Black men with metastatic castration-resistant #prostatecancer treated with #Zytiga showed a surprising result compared to white men. #PCSM https://t.co/58DCr7LNYl
-
-
Mashup Score: 3Share your story - The Institute of Cancer Research, London - 3 year(s) ago
Share your cancer story with us and volunteer to take part in our communications activity. You can help us attract more support and funding for our vital work.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📢 Are you being treated with the drug #abiraterone (also known as #Zytiga) for advanced #ProstateCancer? Please get in touch urgently if you'd be happy to share your story with the media. #CancerTreatment https://t.co/wEwwvRNrK4
-
-
Mashup Score: 0AKT Inhibition Gets Narrow Win in First-Line mCRPC - 4 year(s) ago
Abiraterone plus ipatasertib improved rPFS in men with PTEN loss
Source: www.medpagetoday.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adding this to #Zytiga modestly improved oncologic outcomes for certain men with these types of #prostatecancer, reported Johann De Bono, MD, PhD, of @royalmarsdenNHS, at #ESMO20. By @icingram. @myESMO #PCSM https://t.co/6lx69qJsp8
-
The @US_FDA Oncologic Drugs Advisory Committee recommends first-line olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer should be restricted to men whose tumors harbor BRCA mutations. #Lynparza #Zytiga https://t.co/pZfxKIYUEt